EUVIMEDEUVIMED entdecken
Crossref

Impact of tumour volume on outcomes in patients with locally advanced non-small cell lung cancer receiving chemoradiotherapy and consolidation durvalumab

Vincent Legendre iD, Angela Botticella, Kristi Beshiri, Pernelle Lavaud, Mihaela Aldea, Jérôme Gambini, Cécile Le Péchoux, Antonin Levy iD

British Journal of Radiology · 01.05.2026 · 99 (1181) · 999-1005

DOI: 10.1093/bjr/tqag048 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Radiology, online erschienen am 15.03.2026. Verfasst von Vincent Legendre und 7 weiteren Autor:innen. Beteiligte Einrichtung: Département d'Oncologie-Radiothérapie, Université Paris-Saclay, Gustave Roussy, Villejuif, 94805, France. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Antibodies, Monoclonal, Chemoradiotherapy. Die Arbeit nennt 34 Literaturangaben. Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The standard of care for unresectable locally advanced non-small-cell lung cancer (LA-NSCLC) is chemoradiotherapy (CRT) followed by consolidation immunotherapy. We analysed clinical, biological, and dosimetric data to identify survival predictors and inform personalized treatment strategies.

Methods

We retrospectively reviewed LA-NSCLC patients treated between December 2015 and January 2023. Data were extracted from electronic medical records. Progression-free survival (PFS) and overall survival (OS) were calculated from diagnosis. Kaplan-Meier estimates and Cox proportional hazards models were used for survival analysis.

Results

We included 92 patients (median follow-up: 28.9 months); 66% were male, 60% former smokers, and the median age was 64. Stage IIIB (50%) and adenocarcinoma (60%) were most common. PD-L1 positivity was observed in 75%, and 27% had oncogenic drivers (KRAS: 24%, EGFR: 3%). Most (86%) received concurrent CRT, typically cisplatin-based (60%). Median durvalumab duration was 9.5 months. Median PFS and OS were 31.9 and 51.2 months, respectively. Overall, 47% of patients experienced recurrence, including 15% locoregional recurrence and 85% metastatic recurrence (60% oligometastatic and 25% polymetastatic). PFS was longer in patients aged <66 years (45.4 vs 16.0 months; P = .01), with pre-RT lymphocyte counts >1.80 G/L (45.4 vs 27.7 months; P = .047), or PTV <450 cc (44.3 vs 16.1 months; P = .01). On multivariate analysis, only radiotherapy planning target volume (PTV) <450 cc remained significant (HR: 0.45; P = .04). No factor was associated with OS in multivariable analysis.

Conclusions

Smaller PTV was independently associated with longer PFS, supporting its value in personalized care for LA-NSCLC. Advances in knowledge PTV emerged as an independent prognostic factor for PFS, suggesting its utility in risk stratification and individualized treatment planning.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsCarcinoma, Non-Small-Cell LungAntibodies, MonoclonalChemoradiotherapyAntineoplastic Agents, ImmunologicalTumor BurdenHumansMaleRetrospective StudiesFemaleMiddle AgedAgedProgression-Free SurvivalConsolidation ChemotherapyTreatment Outcome

Stichwörter der Autor:innen

EGFR mutationKRAS mutationPET-CTbiomarkershypoxiaimmunotherapylymphopenianeutrophil-to-lymphocyte ratiopersonalized treatmentprognostic factorsradiation-induced toxicitytumour burden

Substanzen

Antibodies, MonoclonaldurvalumabAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Département d'Oncologie-Radiothérapie, Université Paris-Saclay, Gustave Roussy, Villejuif, 94805, France.
  • Faculty of Medicine, Paris Cité University, Paris, 75006, France.
  • Département d'Oncologie Médicale, Université Paris-Saclay, Gustave Roussy, Villejuif, 94805, France.
  • Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, 94270, France.
  • Electronics Architecture, Modeling and Data Analysis Laboratory, CEA, Gif-sur-Yvette, 91191, France.
  • Université Paris-Saclay, Inserm U1355, Gustave Roussy, Villejuif, 94805, France.

ORCID-Profile: Vincent Legendre, Antonin Levy

Förderung

  • AstraZeneca

Zitieren

APA

Legendre, V., Botticella, A., Beshiri, K., Lavaud, P., Aldea, M., Gambini, J., Le Péchoux, C., & Levy, A. (2026). Impact of tumour volume on outcomes in patients with locally advanced non-small cell lung cancer receiving chemoradiotherapy and consolidation durvalumab. British Journal of Radiology, 99(1181), 999-1005. https://doi.org/10.1093/bjr/tqag048

Vancouver

Legendre V, Botticella A, Beshiri K, Lavaud P, Aldea M, Gambini J, et al. Impact of tumour volume on outcomes in patients with locally advanced non-small cell lung cancer receiving chemoradiotherapy and consolidation durvalumab. British Journal of Radiology. 2026;99(1181):999-1005. doi:10.1093/bjr/tqag048

BibTeX
@article{Legendre2026,
  author = {Legendre, Vincent and Botticella, Angela and Beshiri, Kristi and Lavaud, Pernelle and Aldea, Mihaela and Gambini, Jérôme and Le Péchoux, Cécile and Levy, Antonin},
  title = {Impact of tumour volume on outcomes in patients with locally advanced non-small cell lung cancer receiving chemoradiotherapy and consolidation durvalumab},
  journal = {British Journal of Radiology},
  year = {2026},
  volume = {99},
  number = {1181},
  pages = {999--1005},
  doi = {10.1093/bjr/tqag048}
}
Kostenlos starten →